Stock CASI CASI PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus CASI Pharmaceuticals, Inc.

Equities

CASI

KYG1933S1012

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-04-29 EDT 		5-day change 1st Jan Change
2.34 USD -3.31% Intraday chart for CASI Pharmaceuticals, Inc. -3.70% -67.32%
03-28 CASI Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
03-05 Top Midday Gainers MT

Evolution of the average Target Price on CASI Pharmaceuticals, Inc.

Price target over the last 5 years

History of analyst recommendation changes

c7220b84a5329.jB7omT-AC5kRX463DHfwRRhCtgiaBD_AMcfpyIcPEz4.y1uk_1LXQ8B1KOnyQhGZNX4j-WzfQ0j3a6-eqs9OZ3vtK6Hgdc8zrV0Aww~4a48c1b98e44d11368f77b9c39e962aa

Analyst Recommendations on CASI Pharmaceuticals, Inc.

HC Wainwright Raises Price Target on CASI Pharmaceuticals to $12 From $10, Keeps Buy Rating MT
BTIG Adjusts CASI Pharmaceuticals' Price Target to $10 From $21, Keeps Buy Rating MT
CORRECTION : BTIG Lowers CASI Pharmaceuticals' Price Target to $21 From $40, Buy Rating Kept MT
HC Wainwright Lowers CASI Pharmaceuticals' Price Target to $12 From $30, Buy Rating Maintained MT
Oppenheimer Adjusts CASI Pharmaceuticals' Price Target to $35 From $6 After Reverse Stock Split, Maintains Outperform Rating MT
BTIG Raises CASI Pharmaceuticals' Price Target to $21 From $40, Buy Rating Kept MT
HC Wainwright Adjusts CASI Pharmaceuticals' Price Target to $3 from $4, Keeps Buy Rating MT
CASI PHARMACEUTICALS : BTIG Initiates CASI Pharmaceuticals at Buy Rating With $4 Price Target MT
CASI PHARMACEUTICALS : HC Wainwright Adjusts CASI Pharmaceuticals PT to $4 From $3.50, Maintains Buy Rating MT
CASI PHARMACEUTICALS : Mizuho Security Initiates Coverage on CASI Pharmaceuticals With Buy Rating, $3.80 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
2.34 USD
Average target price
12 USD
Spread / Average Target
+412.82%
High Price Target
12 USD
Spread / Highest target
+412.82%
Low Price Target
12 USD
Spread / Lowest Target
+412.82%

Consensus detail

Consensus revision (last 18 months)

Analysts covering CASI Pharmaceuticals, Inc.

HC Wainwright
BTIG
Oppenheimer
Mizuho Securities

Ratings for CASI Pharmaceuticals, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. CASI Stock
  4. Consensus CASI Pharmaceuticals, Inc.